TY - JOUR
T1 - Neoadjuvant Radiation Lobectomy As an Alternative to Portal Vein Embolization in Hepatocellular Carcinoma
AU - Gabr, Ahmed
AU - Polineni, Praneet
AU - Mouli, Samdeep K
AU - Riaz, Ahsun
AU - Lewandowski, Robert J
AU - Salem, Riad
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Surgical resection is considered first line and potentially curative for early stage hepatocellular carcinoma. However, many patients presenting with small tumors might not qualify as candidates for surgical resection given their small future liver remnant (FLR); such patients tend to undergo neoadjuvant therapies prior to resection to minimize the risk of hepatic decompensation after major hepatic resection. While there are several techniques for inducing FLR hypertrophy, a recent approach in hepatocellular carcinoma is Y90 radiation lobectomy (RL). RL was discovered serendipitously after noticing contralateral lobar hypertrophy in patients who had ipsilateral lobar Y90 radioembolization. This is now proactively used in bridging patients to surgical resection by inducing FLR hypertrophy. In this article we discuss the evolution of RL as an alternative to portal vein embolization which has been long used to induce FLR hypertrophy, albeit mostly in metastatic liver disease.
AB - Surgical resection is considered first line and potentially curative for early stage hepatocellular carcinoma. However, many patients presenting with small tumors might not qualify as candidates for surgical resection given their small future liver remnant (FLR); such patients tend to undergo neoadjuvant therapies prior to resection to minimize the risk of hepatic decompensation after major hepatic resection. While there are several techniques for inducing FLR hypertrophy, a recent approach in hepatocellular carcinoma is Y90 radiation lobectomy (RL). RL was discovered serendipitously after noticing contralateral lobar hypertrophy in patients who had ipsilateral lobar Y90 radioembolization. This is now proactively used in bridging patients to surgical resection by inducing FLR hypertrophy. In this article we discuss the evolution of RL as an alternative to portal vein embolization which has been long used to induce FLR hypertrophy, albeit mostly in metastatic liver disease.
UR - http://www.scopus.com/inward/record.url?scp=85061052404&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061052404&partnerID=8YFLogxK
U2 - 10.1053/j.semnuclmed.2019.01.009
DO - 10.1053/j.semnuclmed.2019.01.009
M3 - Review article
C2 - 30954185
AN - SCOPUS:85061052404
SN - 0001-2998
VL - 49
SP - 197
EP - 203
JO - Seminars in Nuclear Medicine
JF - Seminars in Nuclear Medicine
IS - 3
ER -